Lotus Pharm — Proxy Solicitation & Information Statement 2026

May 15, 2026

In case of any discrepancy between the English and the Chinese version, the Chinese version shall prevail.

Lotus

PHARMACEUTICAL

Meeting Notice for Annual Shareholders' Meeting

(Summary)

Time: 9:00 a.m.

Date: Tuesday, June 16th, 2026

Location: No. 2, Wenxian Rd., Nantou City, Nantou County, Taiwan (R.O.C.)

(Central Taiwan Innovation Campus B134 Training Room)

Reporting Items

1. 2025 business and financial report.
2. Audit and Risk Committee’s review report on 2025 financial statements.
3. 2025 profit distributable as employees’ and directors’ compensation.
4. 2025 distribution of cash dividends.

Recognition Items

1. To adopt FY2025 business report and financial statements.
2. To adopt FY2025 earnings distribution.

Discussion Items

1. Proposal for capital increase through capitalization of retained earnings.
2. The proposed amendments to certain articles of the Company’s “Articles of Incorporation” (“AOI”).
3. The proposed amendments to certain articles of the Company’s “Procedures for Loaning of Funds and Making of Endorsements and Guarantees”.
4. The proposed amendments to certain articles of the Company’s “Procedures for Acquisition or Disposal of Assets”.

---

1. Proposal for releasing the non-compete restriction on directors.
2. Proposal for transfer of shares to employees at the price lower than the average acquisition cost.

Special Motions

Adjournment

Voting Information

Voting Items :
1. To adopt FY2025 business report and financial statements.	☐For	☐Against	☐Abstain
2. To adopt FY2025 earnings distribution.	☐For	☐Against	☐Abstain
3. Proposal for capital increase through capitalization of retained earnings.	☐For	☐Against	☐Abstain
4. The proposed amendments to certain articles of the Company’s “Articles of Incorporation” (“AOI”).	☐For	☐Against	☐Abstain
5. The proposed amendments to certain articles of the Company’s “Procedures for Loaning of Funds and Making of Endorsements and Guarantees”	☐For	☐Against	☐Abstain
6. The proposed amendments to certain articles of the Company’s “Procedures for Acquisition or Disposal of Assets”	☐For	☐Against	☐Abstain
7. Proposal for releasing the non-compete restriction on directors.	☐For	☐Against	☐Abstain
8. Proposal for transfer of shares to employees at the price lower than the average acquisition cost.	☐For	☐Against	☐Abstain

Board of Directors

Lotus Pharmaceutical Co., Ltd.